|
**Overview**: Human Leukocyte Antigen T B Cell AHG Crossmatch Panel**Introduction**: The Human Leukocyte Antigen T B Cell AHG Crossmatch Panel is a diagnostic tool designed for enhanced transplant compatibility testing using whole blood samples. In India, AHG (anti-human globulin) enhancement increases sensitivity of T/B cell crossmatch to detect low-titer or non-complement-fixing antibodies, critical for high-sensitized recipients. High morbidity from under-utilization in rural/low-SES transplant programs, limited advanced crossmatch labs, delayed identification of incompatibility leading to hyperacute rejection or graft loss. Per immunology practices aligned with ICMR and Indian Society of Organ Transplantation guidelines, the test employs immunoassay with AHG enhancement for T-cell/B-cell crossmatch, compatibility markers over 1-2 days with high sensitivity, valuable for pre-transplant risk assessment in sensitized patients. This diagnostic falls under transplant screening and targets high-PRA recipients, addressing accurate detection to guide desensitization or donor selection. With elevated morbidity due to incompatibility risks, the test supports public health efforts by enabling enhanced compatibility profiling and improving graft survival. Its whole blood-based approach ensures reliable crossmatch.**Other Names**: HLA AHG Cross Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: AHG-enhanced crossmatch standard; in India, used in high-sensitized cases.**Purpose**: The test assesses 6 parameters including T-Cell Crossmatch to guide enhanced transplant compatibility assessment, detect low-titer antibodies, inform desensitization.**Test Parameters**: 1. T-Cell Crossmatch, 2. B-Cell Crossmatch, 3. AHG Enhancement, 4â€"6. Compatibility Markers.**Pretest Condition**: No fasting required; patients should be transplant candidates with high PRA.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for crossmatch).**Medical History**: Patients should provide details on sensitization events, prior transplants.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected antibodies including rejection, benefits of enhanced testing, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using immunoassay with AHG by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell viability can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive AHG-enhanced crossmatch indicates high risk, necessitating specialist input.**Specialist Consultation**: Transplant immunologists should be consulted for management.**Additional Supporting Tests**: DSA, flow crossmatch for confirmation.**Test Limitations**: Time-sensitive; comprehensive approach required.**References**: Indian Journal of Transplantation 2024, Transplant Studies India 2023. |
